Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer

PLoS One. 2017 Dec 22;12(12):e0189631. doi: 10.1371/journal.pone.0189631. eCollection 2017.

Abstract

Background: A recent Cochrane review compared laparoscopic versus open distal pancreatectomy for people with for cancers of the body and tail of the pancreas and found that laparoscopic distal pancreatectomy may reduce the length of hospital stay. We compared the cost-effectiveness of laparoscopic distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer.

Method: Model based cost-utility analysis estimating mean costs and quality-adjusted life years (QALYs) per patient from the perspective of the UK National Health Service. A decision tree model was constructed using probabilities, outcomes and cost data from published sources. A time horizon of 5 years was used. One-way and probabilistic sensitivity analyses were undertaken.

Results: The probabilistic sensitivity analysis showed that the incremental net monetary benefit was positive (£3,708.58 (95% confidence intervals (CI) -£9,473.62 to £16,115.69) but the 95% CI includes zero, indicating that there is significant uncertainty about the cost-effectiveness of laparoscopic distal pancreatectomy versus open distal pancreatectomy. The probability laparoscopic distal pancreatectomy was cost-effective compared to open distal pancreatectomy for pancreatic cancer was between 70% and 80% at the willingness-to-pay thresholds generally used in England (£20,000 to £30,000 per QALY gained). Results were sensitive to the survival proportions and the operating time.

Conclusions: There is considerable uncertainty about whether laparoscopic distal pancreatectomy is cost-effective compared to open distal pancreatectomy for pancreatic cancer in the NHS setting.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Cost-Benefit Analysis*
  • Humans
  • Length of Stay
  • Pancreatectomy / economics*
  • Pancreatectomy / methods*
  • Pancreatic Neoplasms / surgery*
  • Quality-Adjusted Life Years
  • Treatment Outcome
  • United Kingdom